Table 1.
Baseline cohort characteristics, overall and according to clinical trials enrolment
| Whole cohort | According to clinical trial enrolment |
|||
|---|---|---|---|---|
| N (%) | Yes | No | P∗ | |
| Total | 9516 | 1716 (18.0) | 7800 (82.0) | |
| Age at diagnosis, years | ||||
| Median (Q1-Q3) | 57.0 (48.5-65.5) | 57.7 (48.1-66.3) | 56.8 (48.6-65.4) | 0.1080 |
| Missing | — | — | — | |
| Age at diagnosis, years | ||||
| <40 | 672 (7.1) | 136 (20.2) | 536 (79.8) | 0.0021 |
| 40-50 | 2145 (22.5) | 384 (17.9) | 1761 (82.1) | |
| 50-65 | 4154 (43.7) | 688 (16.6) | 3466 (83.4) | |
| ≥65 | 2545 (26.7) | 508 (20.0) | 2037 (80.0) | |
| Missing | — | — | — | |
| BMI at diagnosis | ||||
| Median (Q1-Q3) | 24.8 (22.0-28.7) | 25.3 (22.3–29.1) | 24.7 (21.9-28.7) | 0.0012 |
| Missing | 55 | 4 | 51 | |
| BMI at diagnosis | ||||
| <25 | 4832 (51.1) | 815 (16.9) | 4017 (83.1) | 0.0015 |
| ≥25 | 4629 (48.9) | 897 (19.4) | 3732 (80.6) | |
| Missing | 55 | 4 | 51 | |
| Menopausal status | ||||
| Premenopausal | 3514 (37.2) | 617 (17.6) | 2897 (82.4) | 0.3161 |
| Postmenopausal | 5925 (62.8) | 1089 (18.4) | 4836 (81.6) | |
| Missing | 77 | 10 | 67 | |
| Charlson comorbidity index | ||||
| 0 | 7049 (80.8) | 1202 (17.0) | 5849 (83.0) | 0.0210 |
| 1+ | 1672 (19.2) | 325 (19.4) | 1347 (80.6) | |
| Missing | 795 | 189 | 606 | |
| Depression, categorical | ||||
| Normal | 7087 (81.6) | 1301 (18.4) | 5786 (81.6) | 0.3774 |
| Doubtful case/case | 1602 (18.4) | 279 (17.4) | 1323 (82.6) | |
| Missing | 827 | 136 | 691 | |
| HADS depression scorea | ||||
| Mean (SD) | 4.2 (3.7) | 4.1 (3.6) | 4.3 (3.7) | 0.0647 |
| Missing | 827 | 136 | 691 | |
| Anxiety, categorical | ||||
| Normal | 3434 (39.5) | 661 (19.2) | 2773 (80.8) | 0.0394 |
| Doubtful case/case | 5250 (60.5) | 919 (17.5) | 4331 (82.5) | |
| Missing | 832 | 136 | 696 | |
| HADS anxiety scorea | ||||
| Mean (SD) | 9.0 (4.2) | 8.7 (4.2) | 9.0 (4.2) | 0.0205 |
| Missing | 832 | 136 | 696 | |
| Marital status | ||||
| In a relationship | 6786 (77.9) | 1236 (18.2) | 5550 (81.8) | 0.8015 |
| Not in a relationship | 1928 (22.1) | 356 (18.5) | 1572 (81.5) | |
| Missing | 802 | 124 | 678 | |
| Having a child | ||||
| Yes | 8313 (96.5) | 1524 (18.3) | 6789 (81.7) | 0.8324 |
| No | 303 (3.5) | 57 (18.8) | 246 (81.2) | |
| Missing | 900 | 135 | 765 | |
| Familiar history of breast cancer | ||||
| Positive | 2122 (22.7) | 379 (17.9) | 1743 (82.1) | 0.8419 |
| Negative | 7230 (77.3) | 1305 (18.0) | 5925 (82.0) | |
| Missing | 164 | 32 | 132 | |
| Personal history of previous cancer | ||||
| Yes | 735 (7.9) | 118 (16.0) | 617 (84.0) | 0.1607 |
| No | 8613 (92.1) | 1561 (18.1) | 7052 (81.9) | |
| Missing | 168 | 37 | 131 | |
| Previous breast surgery | ||||
| Yes | 694 (7.3) | 94 (13.5) | 600 (86.5) | 0.0014 |
| No | 8776 (92.7) | 1615 (18.4) | 7161 (81.6) | |
| Missing | 46 | 7 | 39 | |
| Highest education level | ||||
| Primary or lower | 1285 (14.8) | 255 (19.8) | 1030 (80.2) | 0.0605 |
| High school | 4029 (46.6) | 751 (18.6) | 3278 (81.4) | |
| College graduate or higher | 3341 (38.6) | 571 (17.1) | 2770 (82.9) | |
| Missing | 861 | 139 | 722 | |
| Monthly household income (euros/month) | ||||
| <2000 | 2288 (28.6) | 430 (18.8) | 1858 (81.2) | 0.0763 |
| 2000-4000 | 3730 (46.6) | 710 (19.0) | 3020 (81.0) | |
| ≥4000 | 1990 (24.8) | 332 (16.7) | 1658 (83.3) | |
| Missing | 1508 | 244 | 1264 | |
| Occupational class | ||||
| Chief executives, managers, and intellectual professions | 3925 (45.1) | 668 (17.0) | 3257 (83.0) | 0.0020 |
| Middle-class workersb | 3249 (37.4) | 612 (18.8) | 2637 (81.2) | |
| Self employed and manual workersc | 1365 (15.7) | 270 (19.8) | 1095 (80.2) | |
| Unemployed, retired | 160 (1.8) | 43 (26.9) | 117 (73.1) | |
| Missing | 817 | 123 | 694 | |
| Region of residency | ||||
| Île-de-France | 2632 (27.7) | 391 (14.9) | 2241 (85.1) | <0.0001 |
| Centre/North of Franced | 4989 (52.4) | 940 (18.8) | 4049 (81.2) | |
| South of Francee | 1895 (19.9) | 385 (20.3) | 1510 (79.7) | |
| Missing | — | — | — | |
| Anonymized COC | ||||
| High volume | 2320 (24.4) | 373 (16.1) | 1947 (83.9) | 0.0004 |
| Intermediate volume | 6454 (67.8) | 1232 (19.1) | 5222 (80.9) | |
| Low volume | 742 (7.8) | 111 (15.0) | 631 (85.0) | |
| Missing | — | — | — | |
| COC and patients region of residence | ||||
| COC in the same region | 8591 (90.3) | 1550 (18.0) | 7041 (82.0) | 0.9424 |
| COC in a different region/foreign patients | 925 (9.7) | 166 (17.9) | 759 (82.1) | |
| Missing | — | — | — | |
| Tumour stage | ||||
| I | 4582 (48.7) | 644 (14.0) | 3938 (86.0) | <0.0001 |
| II | 3911 (41.6) | 864 (22.1) | 3047 (77.9) | |
| III | 912 (9.7) | 188 (20.6) | 724 (79.4) | |
| Missing | 111 | 20 | 91 | |
| Tumour subtype | ||||
| HR+/HER− | 7186 (76.0) | 1318 (18.3) | 5868 (81.7) | 0.0951 |
| HR±/HER2+ | 1317 (13.9) | 248 (18.8) | 1069 (81.2) | |
| HR−/HER2− | 954 (10.1) | 149 (15.6) | 805 (84.4) | |
| Missing | 59 | 1 | 58 | |
| Chemotherapy | ||||
| Yes | 5041 (53.0) | 997 (19.8) | 4044 (80.2) | <0.0001 |
| No | 4475 (47.0) | 719 (16.1) | 3756 (83.9) | |
| Missing | — | — | — | |
| Surgery | ||||
| Mastectomy | 2539 (26.7) | 456 (18.0) | 2083 (82.0) | 0.9100 |
| Conservative surgery | 6971 (73.3) | 1259 (18.1) | 5712 (81.9) | |
| Missing | 6 | 1 | 5 | |
| Hormone therapy | ||||
| Yes | 7679f (81.0) | 1442 (18.8) | 6237 (81.2) | 0.0003 |
| No | 1797g (19.0) | 272 (15.1) | 1525 (84.9) | |
| Missing | 40 | 2 | 38 | |
| Radiotherapy | ||||
| Yes | 8661 (91.2) | 1630 (18.8) | 7031 (81.2) | <0.0001 |
| No | 831 (8.8) | 82 (9.9) | 749 (90.1) | |
| Missing | 24 | 4 | 20 | |
| Anti-HER2 therapy | ||||
| Yes | 1158 (12.2) | 230 (19.9) | 928 (80.1) | 0.0879 |
| No | 8341 (87.8) | 1485 (17.8) | 6856 (82.2) | |
| Missing | 17 | 1 | 16 | |
BMI, body mass index; COC, centre of care; HADS, Hospital Anxiety and Depression Scale; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; Q1-Q3, interquartile range; SD, standard deviation.
Anxiety and depression were assessed using the Hospital Anxiety and Depression Scale (HADS).20
Includes clerks, service and sales workers, technicians, and associates.
Includes farmers, workers, freelancers, artisans, and merchants.
Centre/North of France includes Brittany, Normandy, Hauts de France, Pays de la Loire, Grand Est, Bourgogne-Franche-Comtè, Centre-Val de Loire, and other regions or foreign countries.
South of France includes Provence-Alpes-Cote d'Azur, Occitaine, Corsica, Novelle Aquitaine, and Auvergne-Rhône-Alpes.
Some 87.3% had an HR+ HER2− early breast cancer and 12.7% an HR+ HER2+ early breast cancer.
Some 6.6% had an HR+ HER2− early breast cancer, 29.2% an HR+ HER2+ early breast cancer, and 95.2% a triple-negative breast cancer.
Chi square for categorical variables, Wilcoxon rank sum test for continuous variables.